Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging Alcon (ALC) This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for October 23rd

by Zacks Equity Research

MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.

Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.

Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug

by Zacks Equity Research

CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.

Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod

by Zacks Equity Research

The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.

Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls

by Zacks Equity Research

Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.

Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study

by Zacks Equity Research

Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.

Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade

by Zacks Equity Research

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit

by Zacks Equity Research

Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

by Zacks Equity Research

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

Wall Street Analysts Believe Alpine Immune Sciences, Inc. (ALPN) Could Rally 50.37%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 50.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

by Zacks Equity Research

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.

Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?

by Zacks Equity Research

Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.

Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio

by Zacks Equity Research

Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

by Zacks Equity Research

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

by Zacks Equity Research

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

by Zacks Equity Research

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

Is it a Good Idea to Invest in KalVista (KALV) Stock Now?

by Zacks Equity Research

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.

Here's Why You Should Invest in Alpine (ALPN) Stock Now

by Zacks Equity Research

Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.

Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics

by Zacks Equity Research

Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.